Hemab Therapeutics Holdings (COAG): Analyst Targets Point to +33% Upside From Recent Levels

Key Takeaways

• The $57 central target is the arithmetic mean of eight verified, Buy-rated analyst price targets reviewed, which range from $46 to $70.
• Shares recently traded near $42.81, so reaching $57 would require roughly 33% upside from the latest close.
• The five most recent targets (August–November 2026) sit higher, between $56 and $70, reflecting fresh initiations from J.P. Morgan, LifeSci Capital, Wedbush, and others.
• Key support comes from lead asset sutacimig's FDA Breakthrough Therapy Designation, an expected Phase 3 start, and a cash runway into 2029.
• Principal risk is that COAG is a clinical-stage biotechnology company with no approved products and persistent net losses.
• For more context on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for additional data and updates.
• Explore Trending AI Robots to see AI-driven trading tools that monitor stocks and ETFs for changing signals.

Analyst Price Targets and Consensus View

COAG is a clinical-stage biotechnology company developing therapies for rare blood coagulation disorders. It completed its initial public offering in May 2026, so its coverage universe is young but quickly expanding, and every reviewed target carries a Buy, Outperform, or Overweight rating. Eight attributable analyst price targets were reviewed, spanning roughly $46 to $70, a wide range that reflects differing assumptions about probability of success and peak sales in ultra-rare indications. The arithmetic mean is about $57.25, rounded to a central target of $57. The most recent revisions skew higher: J.P. Morgan initiated with an Overweight and a $70 target in October 2026, LifeSci Capital initiated with an Outperform and $65 in November 2026, Wedbush raised its target to $64 from $55, H.C. Wainwright raised to $60 from $52, and Rodman & Renshaw initiated at $56. Older targets from Jefferies ($47), Goldman Sachs ($46), and Evercore ISI ($50), set in May–July 2026, sit below the newer cluster. No single firm's figure should be treated as a forecast; the spread simply shows that bullish conviction is high but unproven. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

COAG recently traded near $42.81, leaving about 33% upside to the $57 central target — a substantial move for a company still years from potential commercialization. The path depends heavily on clinical execution. Lead asset sutacimig, a bispecific antibody for Glanzmann thrombasthenia and Factor VII deficiency, received FDA Breakthrough Therapy Designation in March 2026 and is expected to begin a Phase 3 trial in the second half of 2026. A second asset, HMB-002, targets Von Willebrand disease. Hemab reported a third-quarter net loss of $27.3 million, or $0.58 per share, with cash and marketable securities of $430.2 million as of September 30, 2026 — funding the company into 2029 by management's estimate.

What Could Support a Move Toward the Target

The strongest bull case is a de-risked regulatory path and a differentiated, subcutaneous prophylactic profile in diseases with no approved preventive therapy. A successful Phase 3 start for sutacimig, followed by proof-of-concept data in Factor VII deficiency (late 2026 or early 2027) and efficacy data for HMB-002 in Von Willebrand disease, could prompt further upward target revisions. The balance sheet is also a factor: a multi-year cash runway reduces near-term dilution risk. Index inclusion in the Russell 3000 Value benchmark and continued initiation coverage from large firms support visibility and investor sentiment. From what I see, these elements combine to create a compelling setup worth monitoring.

What Could Prevent the Target From Being Reached

The main obstacle is binary clinical risk. If pivotal or proof-of-concept trials miss their endpoints, or if regulators push back on trial design, the probability-weighted valuations underlying most targets would fall sharply. Competition is a secondary concern, notably Incyte's (INCY) Star Therapeutics unit in Von Willebrand disease. As a pre-revenue company with negative EPS and a roughly $2 billion market capitalization, COAG carries valuation sensitivity to any setback, and a wide analyst range indicates genuine uncertainty about how much of the pipeline is already reflected in the price.

Technical Levels and Market Structure

Shares have been volatile since the IPO, trading within a 52-week range of roughly $23.00 to $55.42. A sharp single-day decline of about 12.7% on November 9, 2026, pushed the stock back toward the lower half of that range. The $55 area, near the prior high, acts as the first meaningful resistance zone on any recovery toward the $56–$60 analyst targets, with the $64–$70 targets representing levels beyond the stock's existing trading history.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though firms apply different probability-of-success assumptions. Investors should monitor the expected Phase 3 initiation for sutacimig in Glanzmann thrombasthenia, Factor VII deficiency proof-of-concept data (late 2026 or early 2027), HMB-002 efficacy readouts, HMB-003's investigational new drug filing, and quarterly cash-burn updates. Additional analyst initiations or target revisions after these milestones will help indicate whether the $46–$70 range narrows toward the higher end. I'm watching this closely as the clinical milestones approach.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile clinical-stage name like COAG, this type of signal scanning can help traders spot shifting trend behavior and changing momentum more efficiently than manual review. Traders can use the tool to discover new opportunities, monitor existing positions, and respond to emerging trend changes as they develop. In my experience, integrating these signals into the research process adds another layer of perspective on momentum shifts.

Final Assessment

The $57 central target represents a meaningful but unproven upside of about 33% from the recent price, and it is the arithmetic mean of a genuinely wide analyst range ($46–$70) rather than a precise forecast. The case for reaching it rests on sutacimig's Breakthrough Therapy Designation, an imminent Phase 3 start, and a multi-year cash runway, while the case against rests on binary clinical risk, pre-revenue operations, and competition in Von Willebrand disease. With recent targets clustering between $56 and $70 and older targets lower, the debate is less about direction than about how much clinical de-risking is already priced in. Investors should watch the Phase 3 initiation and the next data readouts for clearer signal.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume